According to a new report, published by KBV research, The Global Endometriosis Market size is expected to reach $2.2 billion by 2028, rising at a market growth of 11.6% CAGR during the forecast period.
The Endometriomas segment is showcasing a CAGR of 11.8% during (2022 - 2028). Except for malignant tumors of the reproductive system, endometriomas may be the most serious hazard to a woman's ability to conceive. The possibility of destroying all of the healthy ovarian tissue, which would result in premature or early ovarian failure, issues with ovulation, or impaired ovarian function, exists with these lesions, which also have a very poor response to medical treatment.
The Oral Contraceptives segment is leading the Global Endometriosis Market by Treatment in 2021 thereby, achieving a market value of $1.2 billion by 2028. The segment growth is the result of the widespread use of oral contraceptives and rises in the incidence of menstrual problems. Due to their effectiveness in preventing the return of pelvic discomfort and endometrial lesions, oral contraceptives are strongly preferred as a first-line treatment for individuals without contraindications.
The Retail Pharmacy segment has shown the growth rate of 11.8% during (2022 - 2028). This can be attributed to the fact that most endometriosis patients receive treatment outside of a hospital setting and that over-the-counter medications are widely available. The number of prescriptions for endometriosis medications is rising, as is knowledge of the condition, and healthcare spending is rising, all of which are driving market expansion.
The North America market dominated the Global Endometriosis Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $853.5 million by 2028. The Europe market is experiencing a CAGR of 11.4% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 12.5% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/endometriosis-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
By Type
By Treatment
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
